What is TRVI's health score?

Trevi Therapeutics, Inc. (TRVI) has a TradeApes health score of 46 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is TRVI's estimated fair value?

Based on our 5-year discounted cash flow model, Trevi Therapeutics, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is TRVI undervalued or overvalued?

Our model currently rates TRVI as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for TRVI... Refresh in a moment for the full analysis.

Trevi Therapeutics, Inc. (TRVI)

Healthcare Inconclusive inconclusive mixed

$14.14

Updated: 2026-05-30

TradeApes Score

Financial Strength

60 Healthy

Operating Trend

40 Weak

Relative Value

40 Weak

Capital Allocation

30 Weak

Risk

65 Healthy

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.